πŸ”¬πŸ§ͺ We’re hiring in Bioanalysis at Pharmidex (Hatfield, UK)!
January 5, 2026

We’re excited to expand our Bioanalytical team and are currently recruiting for two on-site, full-time roles supporting regulated and non-regulated programmes across small and large molecules:


1 - Technical Specialist, Bioanalysis (LC-MS)

This is a senior technical authority role for an experienced LC-MS/MS scientist who enjoys solving complex analytical challenges and shaping technical direction. You’ll lead advanced method development and validation, support regulated studies, and mentor other scientists within a collaborative CRO environment.

Ideal for candidates with:

5+ years of hands-on LC-MS/MS bioanalytical experience

Strong expertise in method development, validation, and troubleshooting

Experience with peptides, oligonucleotides, and large molecules

Solid knowledge of GLP/GCP bioanalysis

CRO experience (strongly preferred)


2 - Bioanalytical Scientist (Regulatory Studies)

This role suits a hands-on bioanalytical scientist with experience delivering high-quality data for GLP/GCP studies. You’ll be involved across the full bioanalytical workflow, from method development to reporting, working closely with internal teams and (depending on experience) clients.

Ideal for candidates with:

A degree in Chemistry or a related discipline

5+ years’ experience in a bioanalytical laboratory

Proven experience supporting GLP and/or GCP studies

Strong LC-MS, sample preparation, and large-molecule expertise

Experience with peptides and oligonucleotides


✨ Why Pharmidex?

At Pharmidex, you’ll join a science-driven CRO where quality, accountability, and technical excellence matter. These roles offer real impact, strong collaboration, and the opportunity to contribute to diverse therapeutic programmes.


πŸ“© Interested?

Please, check the full offers detail at https://www.pharmidex.com/careers-at-pharmidex and send your CV and a short cover note to [email protected]

Feel free to share or tag anyone who might be a great fit!

We are hiring
April 1, 2026
We’re pleased to share that Pharmidex has been selected as a partner in the EIC - European Innovation Council Ecosystem Partnership Programme. Our services are now featured on the EIC Service Catalogue, making them accessible to innovative companies and projects supported by the EIC across Europe. This is a great opportunity to further support cutting-edge biotech and life sciences programmes by providing: πŸ”¬ Preclinical in vivo pharmacology πŸ§ͺ Bioanalysis (LC–MS/MS, qPCR, ELISA) πŸ“Š Translational and mechanistic studies 🧫 Histology and pathology We look forward to working with EIC beneficiaries and contributing to the development of the next generation of therapies. If you are part of the EIC ecosystem and looking for a flexible, science-led CRO partner, we would be delighted to connect.
March 26, 2026
We are delighted to congratulate EpiEndo Pharmaceuticals and the Institute of Pharmaceutical Science, King's College London on the publication of two exciting studies exploring the therapeutic potential of EP395: πŸ“„ “ The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung” published in "Lung" πŸ“„ “Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation” published in "Pulmonary Pharmacology & Therapeutics" These studies provide valuable insights into the role of EP395 in modulating inflammatory responses in respiratory disease, supporting its potential as a novel therapeutic approach. At Pharmidex , we are proud to have contributed to this work through our Respiratory Department, supporting the in vivo studies and helping advance these important findings. We look forward to continuing our collaboration and supporting innovative programmes in respiratory drug discovery and development.
March 24, 2026
We are pleased to share our latest publication: “Magnetic field-induced drug delivery from magnetic microporous nanocomposites through magnetic nanoparticles heating or motion” , published in the journal Materials & Design . This work explores innovative approaches to magnetically triggered drug delivery, leveraging the unique properties of magnetic nanoparticles to enable controlled release through heating and motion mechanisms. These advances have the potential to open new avenues in targeted therapies and precision medicine. We would like to sincerely thank our collaborators for their valuable contributions to this research: -CRCT Université de Toulouse Inserm U1037 CNR -Laboratoire de Physique et Chimie des Nano-Objets (LPCNO) CNRS-UPS-INSA -Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) We are proud to contribute to cutting-edge research at the interface of nanotechnology and drug delivery and we look forward to continuing collaborations that drive innovation in drug discovery and development. πŸ”— Read the full article: https://www.sciencedirect.com/science/article/pii/S0264127526003084?via%3Dihub
More Posts